Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.68 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.65 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.65 |
| ▸ | STAT3 | P40763 | 2/20 | 0.63 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.61 |
| ▸ | TNF | P01375 | 1/20 | 0.61 |
| ▸ | IL1B | P01584 | 1/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19451294 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL29403026 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL21814694 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL24142128 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL19451416 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL23884378 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL17873760 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL23884163 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL22280101 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL29856029 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746882-A1 | INHIBITORS OF SMNDC1 AND THEIR THERAPEUTIC USE | CeMM - Forschungszentrum für Molekulare Medizin GmbH (AT) | 2026-05-27 | — | — | EP | disclosed |
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2025216628-A1 | PROTAC COMPOUNDS | UNIVERSITEIT LEIDEN (NL) | 2025-10-16 | — | — | WO | disclosed |
| US-12351579-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-07-08 | — | — | US | disclosed |
| CN-120092003-A | CDK protein degrading agents, pharmaceutical compositions and therapeutic uses | 拜欧斯瑞克斯公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-116507333-B | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4519273-A1 | KRAS G12D PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-119504710-A | PROTACs compound for targeted degradation of PRMT5 and application thereof | 昆明医科大学 | 2025-02-25 | — | — | CN | disclosed |
| CN-114174281-B | Degradation agent for cyclin-dependent kinase 7 (CDK 7) and use thereof | 达纳-法伯癌症研究公司 | 2025-02-07 | — | — | CN | disclosed |
| EP-4110772-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2023-01-04 | — | — | EP | disclosed |
| CN-113710661-B | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2022-11-22 | — | — | CN | disclosed |
| WO-2022159650-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF eEF1A2 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-07-28 | — | — | WO | disclosed |
| CN-109071552-B | Degradation of cyclin dependent kinase 4/6(CDK4/6) by conjugation of CDK4/6 inhibitors to E3 ligase ligands and methods of use | 达纳－法伯癌症研究所公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-114423463-A | Heterobifunctional compounds as HPK1 degradants | 西奈山伊坎医学院 | 2022-04-29 | — | — | CN | disclosed |
| WO-2022086937-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022068933-A1 | COMPOUNDS AND METHODS OF TREATING DISEASES | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-07 | — | — | WO | disclosed |
| EP-3965824-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | Icahn School of Medicine at Mount Sinai (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114174281-A | Degradation agent for cyclin dependent kinase 7(CDK7) and use thereof | 达纳-法伯癌症研究公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2022042707-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | EZH2, EZH1, EED | CRBN 120/4885DDB1 350/4885HDAC1 73/4885 |
| US-12351579-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885HDAC1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.